<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32494969</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1433-0350</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery</Title>
          <ISOAbbreviation>Childs Nerv Syst</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Treatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease.</ArticleTitle>
        <Pagination>
          <StartPage>2453</StartPage>
          <EndPage>2462</EndPage>
          <MedlinePgn>2453-2462</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00381-020-04687-3</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Malignant peripheral nerve sheath tumors (MPNSTs) are rare yet highly aggressive soft tissue sarcomas. Children with neurofibromatosis type 1 (NF1) have a 10% lifetime risk for development of MPNST. Prognosis remains poor and survival seems worse for NF1 patients.</AbstractText>
          <AbstractText Label="METHODS">This narrative review highlights current practices and pitfalls in the management of MPNST in pediatric NF1 patients.</AbstractText>
          <AbstractText Label="RESULTS">Preoperative diagnostics can be challenging, but PET scans have shown to be useful tools. More recently, functional MRI holds promise as well. Surgery remains the mainstay treatment for these patients, but careful planning is needed to minimize postoperative morbidity. Functional reconstructions can play a role in improving functional status. Radiotherapy can be administered to enhance local control in selected cases, but care should be taken to minimize radiation effects as well as reduce the risk of secondary malignancies. The exact role of chemotherapy has yet to be determined. Reports on the efficacy of chemotherapy vary as some report lower effects in NF1 populations. Promisingly, survival seems to ameliorate in the last few decades and response rates of chemotherapy may increase in NF1 populations when administering it as part of standard of care. However, in metastasized disease, response rates remain poor. New systemic therapies are therefore desperately warranted and multiple trials are currently investigating the role of drugs. Targeted drugs are nevertheless not yet included in first line treatment.</AbstractText>
          <AbstractText Label="CONCLUSION">Both research and clinical efforts benefit from multidisciplinary approaches with international collaborations in this rare malignancy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Martin</LastName>
            <ForeName>Enrico</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-8678-9203</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Plastic and Reconstructive Surgery, University Medical Center Utrecht, G04.126, PO Box 85060, 3508, AB, Utrecht, the Netherlands. e.martin@umcutrecht.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flucke</LastName>
            <ForeName>Uta E</ForeName>
            <Initials>UE</Initials>
            <Identifier Source="ORCID">0000-0003-0315-4307</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Solid Tumors, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coert</LastName>
            <ForeName>J Henk</ForeName>
            <Initials>JH</Initials>
            <Identifier Source="ORCID">0000-0002-1921-9737</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Plastic and Reconstructive Surgery, University Medical Center Utrecht, G04.126, PO Box 85060, 3508, AB, Utrecht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Noesel</LastName>
            <ForeName>Max M</ForeName>
            <Initials>MM</Initials>
            <Identifier Source="ORCID">0000-0003-0503-5838</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Solid Tumors, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Childs Nerv Syst</MedlineTA>
        <NlmUniqueID>8503227</NlmUniqueID>
        <ISSNLinking>0256-7040</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018317" MajorTopicYN="Y">Nerve Sheath Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009456" MajorTopicYN="Y">Neurofibromatosis 1</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018319" MajorTopicYN="Y">Neurofibrosarcoma</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012509" MajorTopicYN="Y">Sarcoma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012983" MajorTopicYN="Y">Soft Tissue Neoplasms</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Emerging therapies</Keyword>
        <Keyword MajorTopicYN="Y">MPNST</Keyword>
        <Keyword MajorTopicYN="Y">NF1</Keyword>
        <Keyword MajorTopicYN="Y">Radiotherapy</Keyword>
        <Keyword MajorTopicYN="Y">Surgical treatment</Keyword>
        <Keyword MajorTopicYN="Y">Systemic treatment</Keyword>
      </KeywordList>
      <CoiStatement>No author has any form of disclosure.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32494969</ArticleId>
        <ArticleId IdType="pmc">PMC7575473</ArticleId>
        <ArticleId IdType="doi">10.1007/s00381-020-04687-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s00381-020-04687-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356:713–715. doi: 10.1038/356713a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/356713a0</ArticleId>
            <ArticleId IdType="pubmed">1570015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006–2021. doi: 10.1002/1097-0142(19860515)57:10&lt;2006::AID-CNCR2820571022&gt;3.0.CO;2-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0142(19860515)57:10&lt;2006::AID-CNCR2820571022&gt;3.0.CO;2-6</ArticleId>
            <ArticleId IdType="pubmed">3082508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311–314. doi: 10.1136/jmg.39.5.311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.39.5.311</ArticleId>
            <ArticleId IdType="pmc">PMC1735122</ArticleId>
            <ArticleId IdType="pubmed">12011145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel MJ, Martin L, Barbarot S, Leheup B, Rodriguez D, Lacombe D, Dollfus H, Pasquier L, Isidor B, Ferkal S, Soulier J, Sanson M, Dieux-Coeslier A, Bièche I, Parfait B, Vidaud M, Wolkenstein P, Upadhyaya M, Vidaud D, members of the NF France Network  NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat. 2010;31:E1506–E1518. doi: 10.1002/humu.21271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.21271</ArticleId>
            <ArticleId IdType="pubmed">20513137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans DGR, Huson SM, Birch JM. Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res. 2012;2:17. doi: 10.1186/2045-3329-2-17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2045-3329-2-17</ArticleId>
            <ArticleId IdType="pmc">PMC3499223</ArticleId>
            <ArticleId IdType="pubmed">23036231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Res. 2013;33:2597–2604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23749914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin E, Muskens IS, Coert JH et al (2018) Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis. Neuro-Oncology Pract:1–10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6656331</ArticleId>
            <ArticleId IdType="pubmed">31386019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin E, Coert JH, Flucke UE, Slooff WBM, de Sande MAJ, Noesel MM, Grünhagen DJ, Wijnen MHWA, Verhoef C. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: a nationwide cohort study. Pediatr Blood Cancer. 2019;67:e28138. doi: 10.1002/pbc.28138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.28138</ArticleId>
            <ArticleId IdType="pubmed">31889416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrari A, Miceli R, Rey A, Oberlin O, Orbach D, Brennan B, Mariani L, Carli M, Bisogno G, Cecchetto G, Salvo GLD, Casanova M, Vannoesel MM, Kelsey A, Stevens MC, Devidas M, Pappo AS, Spunt SL. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer. 2011;47:724–731. doi: 10.1016/j.ejca.2010.11.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2010.11.013</ArticleId>
            <ArticleId IdType="pmc">PMC3539303</ArticleId>
            <ArticleId IdType="pubmed">21145727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, Pollock RE, Lev D. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249:1014–1022. doi: 10.1097/SLA.0b013e3181a77e9a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/SLA.0b013e3181a77e9a</ArticleId>
            <ArticleId IdType="pubmed">19474676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stucky C-CH, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, Wasif N. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19:878–885. doi: 10.1245/s10434-011-1978-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1245/s10434-011-1978-7</ArticleId>
            <ArticleId IdType="pubmed">21861229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107:1065–1074. doi: 10.1002/cncr.22098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.22098</ArticleId>
            <ArticleId IdType="pubmed">16881077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valentin T, Le Cesne A, Ray-Coquard I, et al.  Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO) Eur J Cancer. 2016;56:77–84. doi: 10.1016/j.ejca.2015.12.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2015.12.015</ArticleId>
            <ArticleId IdType="pubmed">26824706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao R, Wang H, Jacobson A, Lietz AP, Choy E, Raskin KA, Schwab JH, Deshpande V, Nielsen GP, DeLaney TF, Cote GM, Hornicek FJ, Chen YLE. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol. 2019;137:61–70. doi: 10.1016/j.radonc.2019.03.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.radonc.2019.03.015</ArticleId>
            <ArticleId IdType="pubmed">31078939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin E, Coert JH, Flucke UE, Slooff WBM, Ho VKY, van der Graaf WT, van Dalen T, van de Sande MAJ, van Houdt WJ, Grünhagen DJ, Verhoef C. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer. 2019;124:77–87. doi: 10.1016/j.ejca.2019.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2019.10.014</ArticleId>
            <ArticleId IdType="pubmed">31760312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisenbarth I, Beyer K, Krone W, Assum G. Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. Am J Hum Genet. 2000;66:393–401. doi: 10.1086/302747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/302747</ArticleId>
            <ArticleId IdType="pmc">PMC1288091</ArticleId>
            <ArticleId IdType="pubmed">10677298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida KI, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y, Oda Y. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013;19:450–461. doi: 10.1158/1078-0432.CCR-12-1067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1067</ArticleId>
            <ArticleId IdType="pubmed">23209032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kluwe L, Friedrich RE, Mautner VF. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. Cancer Genet Cytogenet. 1999;113:65–69. doi: 10.1016/S0165-4608(99)00006-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-4608(99)00006-0</ArticleId>
            <ArticleId IdType="pubmed">10459349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beert E, Brems H, Daniels B, et al.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosom Cancer. 2011;50:1021–1032. doi: 10.1002/gcc.20921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.20921</ArticleId>
            <ArticleId IdType="pubmed">21987445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T, Beert E, Pasmant E, et al.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247–251. doi: 10.1038/nature13561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13561</ArticleId>
            <ArticleId IdType="pubmed">25119042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, Glover TW. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosom Cancer. 1994;10:250–255. doi: 10.1002/gcc.2870100405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.2870100405</ArticleId>
            <ArticleId IdType="pubmed">7522538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masliah-Planchon J, Pasmant E, Luscan A, Laurendeau I, Ortonne N, Hivelin M, Varin J, Valeyrie-Allanore L, Dumaine V, Lantieri L, Leroy K, Parfait B, Wolkenstein P, Vidaud M, Vidaud D, Bièche I. MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. BMC Genomics. 2013;14:473. doi: 10.1186/1471-2164-14-473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2164-14-473</ArticleId>
            <ArticleId IdType="pmc">PMC3744175</ArticleId>
            <ArticleId IdType="pubmed">23848554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Upadhyaya M, Spurlock G, Thomas L, Thomas NST, Richards M, Mautner VF, Cooper DN, Guha A, Yan J. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Hum Mutat. 2012;33:763–776. doi: 10.1002/humu.22044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.22044</ArticleId>
            <ArticleId IdType="pubmed">22331697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R, Wang Q, Belzberg AJ, Chaichana K, Gallia GL, Gokaslan ZL, Riggins GJ, Wolinksy JP, Wood LD, Montgomery EA, Hruban RH, Kinzler KW, Papadopoulos N, Vogelstein B, Bettegowda C. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1170–1172. doi: 10.1038/ng.3116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3116</ArticleId>
            <ArticleId IdType="pmc">PMC4383254</ArticleId>
            <ArticleId IdType="pubmed">25305755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, de Sio L, Koscielniak E, Sotti G, Treuner J. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23:8422–8430. doi: 10.1200/JCO.2005.01.4886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.01.4886</ArticleId>
            <ArticleId IdType="pubmed">16293873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pratt CB, Maurer HM, Gieser P, Salzberg A, Rao BN, Parham D, Thomas PRM, Marcus RB, Cantor A, Pick T, Green D, Neff J, Jenkins JJ. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. Med Pediatr Oncol. 1998;30:201–209. doi: 10.1002/(SICI)1096-911X(199804)30:4&lt;201::AID-MPO1&gt;3.0.CO;2-K.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1096-911X(199804)30:4&lt;201::AID-MPO1&gt;3.0.CO;2-K</ArticleId>
            <ArticleId IdType="pubmed">9473754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spunt SL, Hill DA, Motosue AM, Billups CA, Cain AM, Rao BN, Pratt CB, Merchant TE, Pappo AS. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Clin Oncol. 2002;20:3225–3235. doi: 10.1200/JCO.2002.06.066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2002.06.066</ArticleId>
            <ArticleId IdType="pubmed">12149295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrari A, Casanova M, Collini P, Meazza C, Luksch R, Massimino M, Cefalo G, Terenziani M, Spreafico F, Catania S, Gandola L, Gronchi A, Mariani L, Fossati-Bellani F. Adult-type soft tissue sarcomas in pediatric-age patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol. 2005;23:4021–4030. doi: 10.1200/JCO.2005.02.053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.02.053</ArticleId>
            <ArticleId IdType="pubmed">15767645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Noesel MM, Orbach D, Brennan B, Kelsey A, Zanetti I, de Salvo GL, Gaze MN, Craigie RJ, McHugh K, Francotte N, Collini P, Bisogno G, Casanova M, Ferrari A. Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: an analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. Pediatr Blood Cancer. 2019;66:e27833. doi: 10.1002/pbc.27833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.27833</ArticleId>
            <ArticleId IdType="pubmed">31241238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolberg M, Holand M, Agesen TH, Brekke HR, Liestol K, Hall KS, Mertens F, Picci P, Smeland S, Lothe RA. Survival meta-analyses for &gt;1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro-Oncology. 2013;15:135–147. doi: 10.1093/neuonc/nos287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nos287</ArticleId>
            <ArticleId IdType="pmc">PMC3548581</ArticleId>
            <ArticleId IdType="pubmed">23161774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meis JM, Enzinger FM, Martz KL, Neal JA. Malignant peripheral nerve sheath tumors (malignant schwannomas) in children. Am J Surg Pathol. 1992;16:694–707. doi: 10.1097/00000478-199207000-00008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-199207000-00008</ArticleId>
            <ArticleId IdType="pubmed">1530109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Upadhyaya M, Osborn MJ, Maynard J, Kim MR, Tamanoi F, Cooper DN. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Hum Genet. 1997;99:88–92. doi: 10.1007/s004390050317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004390050317</ArticleId>
            <ArticleId IdType="pubmed">9003501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, Zhu S, Cao Z, Liang Y, Sboner A, Tap WD, Fletcher JA, Huberman KH, Qin LX, Viale A, Singer S, Zheng D, Berger MF, Chen Y, Antonescu CR, Chi P. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1227–1232. doi: 10.1038/ng.3095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3095</ArticleId>
            <ArticleId IdType="pmc">PMC4249650</ArticleId>
            <ArticleId IdType="pubmed">25240281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S.L. C (2016) The challenge of cancer genomics in rare nervous system neoplasms: malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics. Am J Pathol 186:464–477 . doi: 10.1016/j.ajpath.2015.10.023LK - http://sfx.library.uu.nl/utrecht?sid=EMBASE&amp;issn=15252191&amp;id=doi:10.1016%2Fj.ajpath.2015.10.023&amp;atitle=The+challenge+of+cancer+genomics+in+rare+nervous+system+neoplasms%3A+Malignant+peripheral+nerve+sheath+tumors+as+a+paradigm+for+cross-species+comparative+oncogenomics&amp;stitle=Am.+J.+Pathol.&amp;title=American+Journal+of+Pathology&amp;volume=186&amp;issue=3&amp;spage=464&amp;epage=477&amp;aulast=Carroll&amp;aufirst=Steven+L.&amp;auinit=S.L.&amp;aufull=Carroll+S.L.&amp;coden=AJPAA&amp;isbn=&amp;pages=464-477&amp;d</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4816695</ArticleId>
            <ArticleId IdType="pubmed">26740486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldblum J, Weiss S, Folpe AL (2019) Enzinger and Weiss’s Soft Tissue Tumor, 7th Editio. Elsevier Ltd</Citation>
        </Reference>
        <Reference>
          <Citation>Le Guellec S, Decouvelaere A-V, Filleron T, et al.  Malignant peripheral nerve sheath tumor is a challenging diagnosis: a systematic pathology review, immunohistochemistry, and molecular analysis in 160 patients from the French Sarcoma Group database. Am J Surg Pathol. 2016;40:896–908. doi: 10.1097/PAS.0000000000000655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0000000000000655</ArticleId>
            <ArticleId IdType="pubmed">27158754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012;123:295–319. doi: 10.1007/s00401-012-0954-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-012-0954-z</ArticleId>
            <ArticleId IdType="pmc">PMC3629555</ArticleId>
            <ArticleId IdType="pubmed">22327363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez AP, Fritchie KJ. Update on peripheral nerve sheath tumors. Surg Pathol Clin. 2019;12:1–19. doi: 10.1016/j.path.2018.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.path.2018.10.001</ArticleId>
            <ArticleId IdType="pubmed">30709438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Röhrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, Reuss J, Hovestadt V, Jones DTW, Bewerunge-Hudler M, Becker A, Weis J, Mawrin C, Mittelbronn M, Perry A, Mautner VF, Mechtersheimer G, Hartmann C, Okuducu AF, Arp M, Seiz-Rosenhagen M, Hänggi D, Heim S, Paulus W, Schittenhelm J, Ahmadi R, Herold-Mende C, Unterberg A, Pfister SM, von Deimling A, Reuss DE. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 2016;131:877–887. doi: 10.1007/s00401-016-1540-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-016-1540-6</ArticleId>
            <ArticleId IdType="pubmed">26857854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wasa J, Nishida Y, Tsukushi S, Shido Y, Sugiura H, Nakashima H, Ishiguro N. MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. Am J Roentgenol. 2010;194:1568–1574. doi: 10.2214/AJR.09.2724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2214/AJR.09.2724</ArticleId>
            <ArticleId IdType="pubmed">20489098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE. Neurofibromatosis 1. Eur J Hum Genet. 2007;15:131–138. doi: 10.1038/sj.ejhg.5201676LK.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.ejhg.5201676LK</ArticleId>
            <ArticleId IdType="pubmed">16957683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Roman RJ, Shelby Burks S, Debs L, Cajigas I, Levi AD. The risk of peripheral nerve tumor biopsy in suspected benign etiologies. Neurosurgery. 2020;86:E326–E332. doi: 10.1093/neuros/nyz549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuros/nyz549</ArticleId>
            <ArticleId IdType="pubmed">31927583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graham DS, Russell TA, Eckardt MA, Motamedi K, Seeger LL, Singh AS, Bernthal NM, Kalbasi A, Dry SM, Nelson SD, Elashoff D, Levine BD, Eilber FC. Oncologic accuracy of image-guided percutaneous core-needle biopsy of peripheral nerve sheath tumors at a high-volume sarcoma center. Am J Clin Oncol. 2019;42:739–743. doi: 10.1097/COC.0000000000000591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/COC.0000000000000591</ArticleId>
            <ArticleId IdType="pubmed">31436746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spurlock G, Knight SJL, Thomas N, Kiehl TR, Guha A, Upadhyaya M. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol. 2010;136:1869–1880. doi: 10.1007/s00432-010-0846-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-010-0846-3</ArticleId>
            <ArticleId IdType="pubmed">20229272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derlin T, Tornquist K, Munster S, et al.  Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med. 2013;38:e19–e25. doi: 10.1097/RLU.0b013e318266ce84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/RLU.0b013e318266ce84</ArticleId>
            <ArticleId IdType="pubmed">23242059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reinert CP, Schuhmann MU, Bender B, Gugel I, la Fougère C, Schäfer J, Gatidis S. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Eur J Nucl Med Mol Imaging. 2019;46:776–787. doi: 10.1007/s00259-018-4227-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00259-018-4227-5</ArticleId>
            <ArticleId IdType="pubmed">30535768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhargava R, Parham DM, Lasater OE, Chari RS, Chen G, Fletcher BD. MR imaging differentiation of benign and malignant peripheral nerve sheath tumors: use of the target sign. Pediatr Radiol. 1997;27:124–129. doi: 10.1007/s002470050082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s002470050082</ArticleId>
            <ArticleId IdType="pubmed">9028843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, O’Doherty M. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19:390–394. doi: 10.1093/annonc/mdm450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdm450</ArticleId>
            <ArticleId IdType="pubmed">17932395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warbey VS, Ferner RE, Dunn JT, Calonje E, O’Doherty MJ. [18F] FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging. 2009;36:751–757. doi: 10.1007/s00259-008-1038-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00259-008-1038-0</ArticleId>
            <ArticleId IdType="pubmed">19142634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahlawat S, Blakeley JO, Rodriguez FJ, Fayad LM. Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neurology. 2019;93:e1076–e1084. doi: 10.1212/WNL.0000000000008092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008092</ArticleId>
            <ArticleId IdType="pubmed">31395668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broski SM, Johnson GB, Howe BM, Nathan MA, Wenger DE, Spinner RJ, Amrami KK. Evaluation of 18F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors. Skelet Radiol. 2016;45:1097–1105. doi: 10.1007/s00256-016-2394-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00256-016-2394-7</ArticleId>
            <ArticleId IdType="pubmed">27115884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salamon J, Veldhoen S, Apostolova I, Bannas P, Yamamura J, Herrmann J, Friedrich RE, Adam G, Mautner VF, Derlin T. F-18-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol. 2014;24:405–412. doi: 10.1007/s00330-013-3020-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00330-013-3020-x</ArticleId>
            <ArticleId IdType="pubmed">24097302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwabe M, Spiridonov S, Yanik EL, Jennings JW, Hillen T, Ponisio M, McDonald DJ, Dehdashti F, Cipriano CA. How effective are noninvasive tests for diagnosing malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1? Diagnosing MPNST in NF1 patients. Sarcoma. 2019;2019:4627521–4627528. doi: 10.1155/2019/4627521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/4627521</ArticleId>
            <ArticleId IdType="pmc">PMC6636541</ArticleId>
            <ArticleId IdType="pubmed">31354382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Combemale P, Valeyrie-Allanore L, Giammarile F, Pinson S, Guillot B, Goulart DM, Wolkenstein P, Blay JY, Mognetti T. Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1. PLoS One. 2014;9:e85954. doi: 10.1371/journal.pone.0085954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0085954</ArticleId>
            <ArticleId IdType="pmc">PMC3916322</ArticleId>
            <ArticleId IdType="pubmed">24516522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cook GJR, Lovat E, Siddique M, Goh V, Ferner R, Warbey VS. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2017;44:1845–1852. doi: 10.1007/s00259-017-3733-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00259-017-3733-1</ArticleId>
            <ArticleId IdType="pmc">PMC5644685</ArticleId>
            <ArticleId IdType="pubmed">28589254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Well L, Salamon J, Kaul MG, Farschtschi S, Herrmann J, Geier KI, Hagel C, Bockhorn M, Bannas P, Adam G, Mautner VF, Derlin T. Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging. Neuro-Oncology. 2019;21:508–516. doi: 10.1093/neuonc/noy199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noy199</ArticleId>
            <ArticleId IdType="pmc">PMC6422433</ArticleId>
            <ArticleId IdType="pubmed">30496452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sauter ER. Reliable biomarkers to identify new and recurrent cancer. Eur J breast Heal. 2017;13:162–167. doi: 10.5152/ejbh.2017.3635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5152/ejbh.2017.3635</ArticleId>
            <ArticleId IdType="pmc">PMC5648271</ArticleId>
            <ArticleId IdType="pubmed">29082372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frankel S, Smith GD, Donovan J, Neal D (2003) Screening for prostate cancer. Lancet (London, England) 361:1122–1128 10.1016/S0140-6736(03)12890-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12672328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu GCW, Lazare K, Sullivan F. Serum and blood based biomarkers for lung cancer screening: a systematic review. BMC Cancer. 2018;18:181. doi: 10.1186/s12885-018-4024-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-018-4024-3</ArticleId>
            <ArticleId IdType="pmc">PMC5812229</ArticleId>
            <ArticleId IdType="pubmed">29439651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hummel TR, Jessen WJ, Miller SJ, Kluwe L, Mautner VF, Wallace MR, Lazaro C, Page GP, Worley PF, Aronow BJ, Schorry EK, Ratner N. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res. 2010;16:5048–5057. doi: 10.1158/1078-0432.CCR-10-0613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-0613</ArticleId>
            <ArticleId IdType="pmc">PMC4837895</ArticleId>
            <ArticleId IdType="pubmed">20739432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson G, Peng P-C, Huang P-Y, Chien HF, Hua KT, Kuo ML, Chen CT, Lee MJ. Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden. PLoS One. 2014;9:e115916. doi: 10.1371/journal.pone.0115916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0115916</ArticleId>
            <ArticleId IdType="pmc">PMC4281253</ArticleId>
            <ArticleId IdType="pubmed">25551830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S-J, Sawitzki B, Kluwe L, Mautner VF, Holtkamp N, Kurtz A. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med. 2013;11:109. doi: 10.1186/1741-7015-11-109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1741-7015-11-109</ArticleId>
            <ArticleId IdType="pmc">PMC3648455</ArticleId>
            <ArticleId IdType="pubmed">23618374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson KL, Al Sannaa GA, Kivlin CM, et al.  Patterns of recurrence and survival in sporadic, neurofibromatosis type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg. 2017;126:319–329. doi: 10.3171/2015.12.JNS152443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2015.12.JNS152443</ArticleId>
            <ArticleId IdType="pmc">PMC5045773</ArticleId>
            <ArticleId IdType="pubmed">27035165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puffer RC, Graffeo CS, Mallory GW, et al.  Brain metastasis from malignant peripheral nerve sheath tumors. World Neurosurg. 2016;92:580.e1–580.e4. doi: 10.1016/j.wneu.2016.06.069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.wneu.2016.06.069</ArticleId>
            <ArticleId IdType="pubmed">27353552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casali PG, Abecassis N, Aro HT, et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:iv51–iv67. doi: 10.1093/annonc/mdy096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy096</ArticleId>
            <ArticleId IdType="pubmed">29846498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62:1573–1577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11894862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson CN, Dombi E, Rosenblum JS, Miettinen MM, Lehky TJ, Whitcomb PO, Hayes C, Scott G, Benzo S, Widemann BC, Chittiboina P (2019) Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. J Neurosurg:1–11. 10.3171/2019.7.JNS191353</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31653805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42:351–360. doi: 10.1016/S0360-3016(98)00223-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0360-3016(98)00223-5</ArticleId>
            <ArticleId IdType="pubmed">9788415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zehou O, Fabre E, Zelek L, Sbidian E, Ortonne N, Banu E, Wolkenstein P, Valeyrie-Allanore L. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis. 2013;8:127. doi: 10.1186/1750-1172-8-127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1750-1172-8-127</ArticleId>
            <ArticleId IdType="pmc">PMC3766199</ArticleId>
            <ArticleId IdType="pubmed">23972085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puffer RC, Marek T, Stone JJ, Raghunathan A, Howe BM, Spinner RJ. Extensive perineural spread of an intrapelvic sciatic malignant peripheral nerve sheath tumor: a case report. Acta Neurochir. 2018;160:1833–1836. doi: 10.1007/s00701-018-3619-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00701-018-3619-4</ArticleId>
            <ArticleId IdType="pubmed">29974241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin E, Slooff W-BM, van Houdt WJ, van Dalen T, Verhoef C, Coert JH. Oncological treatment considerations differ across surgical subspecialties treating malignant peripheral nerve sheath tumors: an international survey. Sarcoma. 2020;2020:6406439–6406410. doi: 10.1155/2020/6406439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/6406439</ArticleId>
            <ArticleId IdType="pmc">PMC7064831</ArticleId>
            <ArticleId IdType="pubmed">32189989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarkson PW, Griffin AM, Catton CN, O'Sullivan B, Ferguson PC, Wunder JS, Bell RS. Epineural dissection is a safe technique that facilitates limb salvage surgery. Clin Orthop Relat Res. 2005;438:92–96. doi: 10.1097/01.blo.0000180057.22712.53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.blo.0000180057.22712.53</ArticleId>
            <ArticleId IdType="pubmed">16131875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerrand CH, Wunder JS, Kandel RA, O’Sullivan B, Catton CN, Bell RS, Griffin AM, Davis AM. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg (Br) 2001;83:1149–1155. doi: 10.1302/0301-620X.83B8.0831149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1302/0301-620X.83B8.0831149</ArticleId>
            <ArticleId IdType="pubmed">11764430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis Type 1: clinical article. J Neurosurg. 2013;118:142–148. doi: 10.3171/2012.9.JNS101610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2012.9.JNS101610</ArticleId>
            <ArticleId IdType="pubmed">23101443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mundinger GS, Prucz RB, Frassica FJ, Deune EG. Concomitant upper extremity soft tissue sarcoma limb-sparing resection and functional reconstruction: assessment of outcomes and costs of surgery. Hand (N Y) 2014;9:196–204. doi: 10.1007/s11552-013-9567-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11552-013-9567-9</ArticleId>
            <ArticleId IdType="pmc">PMC4022960</ArticleId>
            <ArticleId IdType="pubmed">24839421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin E, Dullaart MJ, van de Sande MAJ, et al (2019) Resuscitating extremities after soft tissue sarcoma resections: are functional reconstructions an overlooked option in limb salvage? A systematic review. Eur J Surg Oncol in press: 10.1016/j.ejso.2019.05.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31178300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin E, Dullaart MJ, Verhoef C, Coert JH. A systematic review of functional outcomes after nerve reconstruction in extremity soft tissue sarcomas: a need for general implementation in the armamentarium. J Plast Reconstr Aesthet Surg. 2020;73:621–632. doi: 10.1016/j.bjps.2019.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bjps.2019.12.010</ArticleId>
            <ArticleId IdType="pubmed">32088187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spiliopoulos K, Williams Z. Brachial plexus reconstruction following resection of a malignant peripheral nerve sheath tumor: case report. Neurosurgery. 2011;69:E245–E250. doi: 10.1227/NEU.0b013e31821867de.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/NEU.0b013e31821867de</ArticleId>
            <ArticleId IdType="pubmed">21796069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costales JR, Socolovsky M, Sanchez Lazaro JA, Alvarez Garcia R. Peripheral nerve injuries in the pediatric population: a review of the literature. Part I: traumatic nerve injuries. Childs Nerv Syst. 2019;35:29–35. doi: 10.1007/s00381-018-3974-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-018-3974-8</ArticleId>
            <ArticleId IdType="pubmed">30215119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slump J, Hofer SOP, Ferguson PC, Wunder JS, Griffin AM, Hoekstra HJ, Bastiaannet E, O'Neill AC. Flap reconstruction does not increase complication rates following surgical resection of extremity soft tissue sarcoma. Eur J Surg Oncol. 2018;44:251–259. doi: 10.1016/j.ejso.2017.11.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejso.2017.11.015</ArticleId>
            <ArticleId IdType="pubmed">29275911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barwick WJ, Goldberg JA, Scully SP, Harrelson JM. Vascularized tissue transfer for closure of irradiated wounds after soft tissue sarcoma resection. Ann Surg. 1992;216:591–595. doi: 10.1097/00000658-199211000-00011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000658-199211000-00011</ArticleId>
            <ArticleId IdType="pmc">PMC1242678</ArticleId>
            <ArticleId IdType="pubmed">1444651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J. K, A. G, M. T, et al (2014) Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol 4: . doi: 10.3389/fonc.2014.00324LK - http://sfx.library.uu.nl/utrecht?sid=EMBASE&amp;issn=2234943X&amp;id=doi:10.3389%2Ffonc.2014.00324&amp;atitle=Radiation+therapy+in+management+of+sporadic+and+neurofibromatosis+type+1-associated+malignant+peripheral+nerve+sheath+tumors&amp;stitle=Front.+Oncol.&amp;title=Frontiers+in+Oncology&amp;volume=4&amp;issue=NOV&amp;spage=&amp;epage=&amp;aulast=Kahn&amp;aufirst=Jenna&amp;auinit=J.&amp;aufull=Kahn+J.&amp;coden=&amp;isbn=&amp;pages=-&amp;date=2014&amp;auinit1=J&amp;auinitm=</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4233912</ArticleId>
            <ArticleId IdType="pubmed">25452937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrari A, Bisogno G, Carli M. Management of childhood malignant peripheral nerve sheath tumor. Paediatr Drugs. 2007;9:239–248. doi: 10.2165/00148581-200709040-00005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00148581-200709040-00005</ArticleId>
            <ArticleId IdType="pubmed">17705563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaushal A, Citrin D. The role of radiation therapy in the management of sarcomas. Surg Clin North Am. 2008;88:629–646. doi: 10.1016/j.suc.2008.03.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.suc.2008.03.005</ArticleId>
            <ArticleId IdType="pmc">PMC2517216</ArticleId>
            <ArticleId IdType="pubmed">18514703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis A, O’Sullivan B, Turcotte R, et al.  Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75:48–53. doi: 10.1016/j.radonc.2004.12.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.radonc.2004.12.020</ArticleId>
            <ArticleId IdType="pubmed">15948265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Sullivan B, Davis AM, Turcotte R, et al.  Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet (London, England) 2002;359:2235–2241. doi: 10.1016/S0140-6736(02)09292-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(02)09292-9</ArticleId>
            <ArticleId IdType="pubmed">12103287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701–711. doi: 10.1056/NEJMra041866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra041866</ArticleId>
            <ArticleId IdType="pubmed">16107623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hawkins DS, Spunt SL, Skapek SX. Children’s Oncology Group’s 2013 blueprint for research: soft tissue sarcomas. Pediatr Blood Cancer. 2013;60:1001–1008. doi: 10.1002/pbc.24435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.24435</ArticleId>
            <ArticleId IdType="pmc">PMC3777409</ArticleId>
            <ArticleId IdType="pubmed">23255356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pratt CB, Pappo AS, Gieser P, Jenkins JJ, Salzberg A, Neff J, Rao B, Green D, Thomas P, Marcus R, Parham D, Maurer H. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17:1219. doi: 10.1200/JCO.1999.17.4.1219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.1999.17.4.1219</ArticleId>
            <ArticleId IdType="pubmed">10561182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97:340–349. doi: 10.1002/jso.20971.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.20971</ArticleId>
            <ArticleId IdType="pubmed">18286466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU, III, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, III, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Tap WD, Wayne JD, Bergman MA, Scavone J. Soft tissue sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2016;14:758–786. doi: 10.6004/jnccn.2016.0078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2016.0078</ArticleId>
            <ArticleId IdType="pubmed">27283169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BC. SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors. Sarcoma. 2017;2017:8685638–8685638. doi: 10.1155/2017/8685638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/8685638</ArticleId>
            <ArticleId IdType="pmc">PMC5613633</ArticleId>
            <ArticleId IdType="pubmed">29138631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim AR, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375:2550–2560. doi: 10.1056/NEJMoa1605943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1605943</ArticleId>
            <ArticleId IdType="pmc">PMC5508592</ArticleId>
            <ArticleId IdType="pubmed">28029918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tap WD, Jones RL, Van Tine BA, et al.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet (London, England) 2016;388:488–497. doi: 10.1016/S0140-6736(16)30587-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)30587-6</ArticleId>
            <ArticleId IdType="pmc">PMC5647653</ArticleId>
            <ArticleId IdType="pubmed">27291997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robertson KA, Nalepa G, Yang F-C, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, Fletcher JW, Travers JB, Staser KW, Lee MW, Sherman MR, Davis CJ, Miller LC, Ingram DA, Clapp DW. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 2012;13:1218–1224. doi: 10.1016/S1470-2045(12)70414-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(12)70414-X</ArticleId>
            <ArticleId IdType="pmc">PMC5380388</ArticleId>
            <ArticleId IdType="pubmed">23099009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Myers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27:3148–3153. doi: 10.1200/JCO.2008.20.5054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2008.20.5054</ArticleId>
            <ArticleId IdType="pubmed">19451433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson MJ, Rhodes SD, Jiang L, Li X, Yuan J, Yang X, Zhang S, Vakili ST, Territo P, Hutchins G, Yang FC, Ingram DA, Clapp DW, Chen S. Preclinical evidence for the use of sunitinib malate in the treatment of plexiform neurofibromas. Pediatr Blood Cancer. 2016;63:206–213. doi: 10.1002/pbc.25763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.25763</ArticleId>
            <ArticleId IdType="pmc">PMC4862309</ArticleId>
            <ArticleId IdType="pubmed">26375012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, Choyke PL, Reddy A, Korf B, Widemann BC. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer. 2013;60:396–401. doi: 10.1002/pbc.24281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.24281</ArticleId>
            <ArticleId IdType="pmc">PMC6309697</ArticleId>
            <ArticleId IdType="pubmed">22961690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahsan S, Ge Y, Tainsky MA. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Oncotarget. 2016;7:57171–57185. doi: 10.18632/oncotarget.11036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.11036</ArticleId>
            <ArticleId IdType="pmc">PMC5302981</ArticleId>
            <ArticleId IdType="pubmed">27494873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albritton KH, Rankin C, Coffin CM, Ratner N, Budd GT, Schuetze SM, Randall RL, Declue JE, Borden EC. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST) J Clin Oncol. 2006;24:9518. doi: 10.1200/jco.2006.24.18_suppl.9518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2006.24.18_suppl.9518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maki RG, D’Adamo DR, Keohan ML, et al.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133–3140. doi: 10.1200/JCO.2008.20.4495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2008.20.4495</ArticleId>
            <ArticleId IdType="pmc">PMC2716936</ArticleId>
            <ArticleId IdType="pubmed">19451436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, Reinke DK, Baker LH. SARC009: phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016;122:868–874. doi: 10.1002/cncr.29858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.29858</ArticleId>
            <ArticleId IdType="pubmed">26710211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin E, Lamba N, Flucke UE, Verhoef C, Coert JH, Versleijen-Jonkers YMH, Desar IME. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): a systematic review from bench to bedside. Crit Rev Oncol Hematol. 2019;138:223–232. doi: 10.1016/j.critrevonc.2019.04.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.critrevonc.2019.04.007</ArticleId>
            <ArticleId IdType="pubmed">31092379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widemann BC, Meyer CF, Cote GM, Chugh R, Milhem MM, van Tine BA, Kim AR, Turpin B, Dombi E, Jayaprakash N, Okuno SH, Helman LJ, Onwudiwe N, Steinberg SM, Reinke DK, Cichowski K, Perentesis JP. SARC016: phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST) J Clin Oncol. 2016;34:11053. doi: 10.1200/JCO.2016.34.15_suppl.11053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.34.15_suppl.11053</ArticleId>
            <ArticleId IdType="pmc">PMC6681622</ArticleId>
            <ArticleId IdType="pubmed">31427883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuchida T, Otsuka H, Niimura M, Inoue Y, Kukita A, Hashimoto Y, Seyama Y, Yamakawa T. Biochemical study on gangliosides in neurofibromas and neurofibrosarcomas of Recklinghausen’s disease. J Dermatol. 1984;11:129–138. doi: 10.1111/j.1346-8138.1984.tb01454.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1346-8138.1984.tb01454.x</ArticleId>
            <ArticleId IdType="pubmed">6434614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children's Oncology Group  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–1334. doi: 10.1056/NEJMoa0911123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0911123</ArticleId>
            <ArticleId IdType="pmc">PMC3086629</ArticleId>
            <ArticleId IdType="pubmed">20879881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Angelo SP, Mahoney MR, Van Tine BA, et al.  Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19:416–426. doi: 10.1016/S1470-2045(18)30006-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30006-8</ArticleId>
            <ArticleId IdType="pmc">PMC6126546</ArticleId>
            <ArticleId IdType="pubmed">29370992</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
